by FDA Approval | 15 August 2024 | Solid Tumors, Women's Cancers
The U.S. Food and Drug Administration (FDA) has recently expanded its indications and granted approvals for three drugs, offering new options for patients with various forms of cancer. The approved drugs—dostarlimab-gxly for endometrial cancer, afamitresgene...
by FDA Approval | 14 June 2024 | Solid Tumors
The FDA has granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This approval targets patients with locally...
by FDA Approval | 13 June 2024 | Solid Tumors
The FDA has approved selpercatinib for both adults and pediatric patients who are 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. This approval comes...
